Navigation Links
GENova appoints Director of Asian business development
Date:9/9/2009

NEW YORK, Sept. 9 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today announced it has hired Mr. Huynho Jin to lead its business expansion in Asia.

Mr. Jin is a respected Korean business man with extensive experience in establishing and managing business operations throughout South East Asia.

"Asia is a lucrative, but often difficult-to-penetrate market due to its strong reliance on personal relationships," says Aaron Whiteman, CEO for GENova. "Mr. Jin's connections and experience in the region will be a boon for GENova. Thanks to Mr. Jin, we now have personal access to hundreds of Asian biotech startups and their promising new drug technologies."

Previously, Mr. Jin was in charge of expanding operations for Bohun Management throughout Asia. He is reputed for his management and negotiation skills, as well as his strong personal business network throughout South East Asia. Mr. Jin will grow GENova's scientific network in Asia, adding to its existing close relationships with research institutions and biotech startups in the UK, U.S., India, Spain, and Denmark.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include but are not limited to the success of the owned intellectual property, the strength of the patents, continued availability of capital and financing, and general economic market or business conditions.


'/>"/>
SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. WorldHeart Appoints David Pellone Chief Financial Officer
7. Novo Nordisk Appoints New Leader of North American Business
8. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
9. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
10. Resonant Medical Appoints New Vice President of Global Sales
11. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... ... Ecommerce sales have grown every year since the 1990’s, with 2016 retail ... of rapid innovation and growth are often neglected in the name of progress. As ... individual’s job to give something back to the planet that provides the resources needed ...
(Date:4/22/2017)... ... ... Juan Capistrano summer camp team at the Boys and Girls Club of South Coast ... physical activities for all campers. To read the report, click here or see ... specialty camps that focus on what the report terms as “sitting subjects” like coding or ...
(Date:4/21/2017)... ... 2017 , ... Contrary to popular perception, a new study ... noteworthy rates. Between 2002 and 2014, Salas-Wright and his colleagues found a 29% ... United States. The study, Trends in Fighting and Violence Among Adolescents in ...
(Date:4/21/2017)... PA (PRWEB) , ... April 21, 2017 , ... ... firm in Allegheny County that offers services to communities throughout the greater Pittsburgh ... in a charity drive to provide adaptive bicycles for differently-abled children. , Variety ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... ... announced it’s been named Agency of Record (AOR) for Theravent, Inc. , ... eliminate snoring. Theravent’s parent company, Foundation Consumer Healthcare, is now working to expand ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... Research and Markets has announced the addition of ... By Service (Manufacturing, Research), By Country, (Brazil, Mexico, Colombia, Argentina, ... to their offering. ... The Latin American pharmaceutical contract manufacturing services market is anticipated ... drug registration cost in Latin American countries and continuous economic ...
(Date:4/19/2017)... 19, 2017 Global Surgical Drainage Device Market: ... used to remove excess liquid and air. The fluid ... bile or lymph. Surgical drains are used in a ... orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common ... prevent accumulation of fluid e.g. blood or pus. Surgical ...
(Date:4/19/2017)... 19, 2017 Companion ... response in pets such as canine, avian and ... various types such as Attenuated Live Vaccines, Conjugate ... Vaccines and Recombinant Vaccines. Attenuated live vaccines are ... bacteria, which have been weakend under laboratory conditions. ...
Breaking Medicine Technology: